StockNews.AI
GMAB
StockNews.AI
155 days

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

1. Genmab reported a 55.6% objective response rate for Rina-S in ovarian cancer. 2. This study updates potential market opportunities for GMAB's innovative cancer treatments.

2m saved
Insight
Article

FAQ

Why Bullish?

The promising data on Rina-S enhances GMAB's growth potential, similar to past ADC successes.

How important is it?

The substantial response rate in a challenging patient demographic strengthens GMAB's value proposition.

Why Long Term?

Positive trial results can lead to FDA approval and expanded market share over time.

Related Companies

REGNAMGNBMY
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug conjugate (ADC) that showed Rina-S 120 mg/m2 every 3 weeks (Q3W) resulted in a confirmed objective response rate (ORR) of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer (OC) patients regardless of FRα expression levels. With a m.

Related News